Rovi sube en Bolsa por el éxito de la vacuna de Moderna
Rovi se convierte en uno de los valores que más sube del Ibex siguiendo la estela de su socio Moderna, que ha presentado los datos preliminares de su vacuna contra el melanoma. Leer
Rovi's stock price surged on the stock exchange due to the success of Moderna's COVID-19 vaccine. The biotechnology company announced preliminary data from early-stage clinical trials of its melanoma vaccine, which caused Rovi's shares to rise by 1.6%, bringing them to 58.10 euros. This marked Rovi as the third highest-growing stock on the Ibex, behind Ferrovial and Repsol.
Rovi's market capitalization now stands at 3.1 billion euros. The company entered into a manufacturing agreement with Moderna in 2020 for the production of its COVID-19 vaccine, and later extended this partnership for ten years to cover all products based on mRNA technology, including the melanoma vaccine.
Written by urgent.news from Expansion ES's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
